Early use of statins in acute coronary syndromes

被引：18

作者：

Joshua M. Spin

Randall H. Vagelos

机构：

[1] Stanford University Medical Center, Flak CVRB-279, Stanford

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 1期

关键词：

Statin; Acute Coronary Syndrome; Simvastatin; Pravastatin; Statin Therapy;

D O I：

10.1007/s11883-003-0068-0

中图分类号：

学科分类号：

摘要：

This review examines the use of statin medications early in the clinical course of acute coronary syndrome (ACS). Available data demonstrate that there are clear clinical benefits to this practice. Numerous previous studies have documented the primary and secondary benefits of statins in the prevention of coronary events. Recent trials show that when statins are used during hospital admissions for ACS, patients experience decreased recurrent myocardial infarction, lower death rates, and fewer repeat hospitalizations for ischemia or revascularization. Several studies suggest that the positive effects of statins on plaque stabilization, inflammation, thrombosis, and endothelial function may be independent of lipid levels. There is also an emerging view that beneficial lipid-lowering with statins in high-risk patients has no lower limit. This information suggests that all patients admitted for ACS should be treated with statins, regardless of cholesterol levels. Copyright © 2003 by Current Science Inc.

引用

页码：44 / 51

页数：7

共 60 条

[21]

Albert M.A., Danielson E., Rifai N., Et al., Effect of statin therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study, JAMA, 286, pp. 64-71, (2001)

[22]

Ridker P.M., Rifai N., Clearfield M., Et al., Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N. Engl. J. Med., 344, pp. 1959-1965, (2001)

[23]

Spinale F.G., Coker M.L., Bond B.R., Et al., Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target, Cardiovasc. Res., 46, pp. 225-238, (2000)

[24]

Lefer A.M., Campbell B., Shin Y.K., Et al., Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts, Circulation, 100, pp. 178-184, (1999)

[25]

Hayashidani S., Tsutsui H., Shiomi T., Et al., Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction, Circulation, 105, pp. 868-873, (2002)

[26]

Belosta S., Via D., Canavesi M., Et al., HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages, Arterioscleros. Thromb. Vasc. Biol., 18, pp. 1671-1678, (1998)

[27]

Fukumoto Y., Libby P., Rabkin E., Et al., Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits, Circulation, 103, pp. 993-999, (2001)

[28]

Crisby M., Nordin-Fredriksson G., Shah P.K., Et al., Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization, Circulation, 103, pp. 926-933, (2001)

[29]

Lacoste L., Lam J.Y., Hung J., Et al., Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction, Circulation, 92, pp. 3172-3177, (1995)

[30]

Dangas G., Badimon J.J., Smith D.A., Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile, J. Am. Coll. Cardiol., 33, pp. 1294-1304, (1999)

← 1 2 3 4 5 6 →